Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company’s Pharmaceutical Technology Center, will cost ₹495 (~$7) per pack.
Cadila Healthcare Managing Director Sharvil Patel commented, “Our focus has always been on helping people lead a better quality of life and making therapies accessible and affordable to people. Our innovations have brought in next-generation therapies in respiratory, women’s healthcare, cardio-metabolic disorders, gastrointestinal and pain management segments. With this new technology, we hope to bring much relief to patients suffering from COPD and help them improve their health and quality of life.”
Read the Zydus Cadila press release.
